Polycythemia vera secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Mahshid |
||
| Line 21: | Line 21: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Hematology]] | |||
Revision as of 15:13, 27 November 2017
|
Polycythemia vera Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Polycythemia vera secondary prevention On the Web |
|
American Roentgen Ray Society Images of Polycythemia vera secondary prevention |
|
Risk calculators and risk factors for Polycythemia vera secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2] Synonyms and keywords: Polycythemia rubra vera (PRV); Erythremia; Primary polycythemia; Osler-Vaquez disease; splenomegalic polycythemia
Overview
Secondary prevention strategy following polycythemia vera include low dose aspirin.[1]
Secondary Prevention
Secondary prevention strategy following polycythemia vera include low dose aspirin to decrease the risk of the following complications:[1]
- Cardiovascular death
- Non-fatal myocardial infarction
- Non-fatal stroke
References
- ↑ 1.0 1.1 Maeda T, Wakasawa T, Shima Y, Tsuboi I, Aizawa S, Tamai I (2006). "Role of polyamines derived from arginine in differentiation and proliferation of human blood cells". Biol Pharm Bull. 29 (2): 234–9. PMID 16462024.